Davis Polk partner Yasin Keshvargar discussed the uptick in biotech IPOs this year and the market outlook for the rest of 2026 with Law360. 

“The pipeline is really robust. There are more biotech companies looking to go public now. The activity in the sector is really heightened,” Yasin noted. “2026 has certainly been a banner year so far.”

Yasin added that he expects the pace of IPOs to continue into the second half of 2026, barring any major roadblocks. “We’re at 12 IPOs and we’re almost at the halfway point of the year. I could be wrong, but if the trends stay the same, we could see 26 IPOs in ‘26,” he said.

“Capital Markets Attys See Steady Momentum For Biotech IPOs,” Law360 (June 16, 2026) (subscription required) 

Copy link to share post